Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial.

Matson, Mark A; Schenker, Eran; Stein, Michal; Zamfirova, Vladislava; Nguyen, Huy-Binh; Bergman, Garrett E

Matson, Mark A; Schenker, Eran; Stein, Michal; Zamfirova, Vladislava; Nguyen, Huy-Binh; Bergman, Garrett E.

Afiliação

Matson MA; Investigator. Prism Research, St. Paul, MN, USA.
Schenker E; Department of Medical Affairs, Kamada Ltd, Beit Kama, MP Negev, Israel.
Stein M; Department of Medical Affairs, Kamada Ltd, Beit Kama, MP Negev, Israel.
Zamfirova V; Department of Medical Affairs, Kedrion Biopharma Inc, Fort Lee, NJ, USA.
Nguyen HB; Department of Medical Affairs, Kedrion Biopharma Inc, Fort Lee, NJ, USA.
Bergman GE; Department of Medical Affairs, Kedrion Biopharma Inc, Fort Lee, NJ, USA.

Hum Vaccin Immunother ; 16(2): 452-459, 2020.

Article em En | MEDLINE | ID: mdl-31549899

Assuntos

Vacina Antirrábica; Vírus da Raiva; Raiva; Anticorpos Antivirais; Voluntários Saudáveis; Humanos; Profilaxia Pós-Exposição; Estudos Prospectivos; Raiva/prevenção & controle; Vacina Antirrábica/efeitos adversos

Palavras-chave

Immunoglobulin; post-exposure prophylaxis; rabies; vaccine; zoonotic disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google